An International Multicenter Evaluation of Type 5 Long QT Syndrome-Reference-Cited by-同舟云学术

An International Multicenter Evaluation of Type 5 Long QT Syndrome

Published:2020-02-11 Issue:6 Volume:141 Page:429-439
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Roberts Jason D.¹,Asaki S. Yukiko²,Mazzanti Andrea³⁴,Bos J. Martijn,Tuleta Izabela⁴⁵,Muir Alison R.⁶,Crotti Lia⁴⁷⁸⁹,Krahn Andrew D.¹⁰,Kutyifa Valentina¹¹,Shoemaker M. Benjamin¹²¹³,Johnsrude Christopher L.¹⁴,Aiba Takeshi¹⁵,Marcondes Luciana¹⁶,Baban Anwar⁴¹⁷,Udupa Sharmila¹⁸,Dechert Brynn¹⁹,Fischbach Peter²⁰,Knight Linda M.²⁰,Vittinghoff Eric²¹,Kukavica Deni³⁴,Stallmeyer Birgit⁴²²,Giudicessi John R.¹²,Spazzolini Carla⁴⁷,Shimamoto Keiko¹⁵,Tadros Rafik²³,Cadrin-Tourigny Julia²³,Duff Henry J.²⁴,Simpson Christopher S.²⁵,Roston Thomas M.¹⁰,Wijeyeratne Yanushi D.⁴²⁶,El Hajjaji Imane¹,Yousif Maisoon D.¹,Gula Lorne J.¹,Leong-Sit Peter¹,Chavali Nikhil¹³,Landstrom Andrew P.²⁷,Marcus Gregory M.²⁸,Dittmann Sven⁴²²,Wilde Arthur A. M.⁴²⁸,Behr Elijah R.⁴²⁶,Tfelt-Hansen Jacob⁴²⁹,Scheinman Melvin M.³⁰,Perez Marco V.³¹,Kaski Juan Pablo⁴³²,Gow Robert M.¹⁸,Drago Fabrizio⁴¹⁷,Aziz Peter F.³³,Abrams Dominic J.³⁴,Gollob Michael H.³⁵,Skinner Jonathan R.¹⁶,Shimizu Wataru¹⁵³⁶,Kaufman Elizabeth S.³⁷,Roden Dan M.¹³³⁸³⁹,Zareba Wojciech¹¹,Schwartz Peter J.⁴⁷,Schulze-Bahr Eric⁴²²,Etheridge Susan P.²,Priori Silvia G.³⁴,Ackerman Michael J.¹²

Affiliation:

1. Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, Ontario, Canada (J.D.R., I.E.H., M.D.Y., L.J.G., P.L.-S.).

2. Department of Pediatrics, University of Utah, and Primary Children’s Hospital, Salt Lake City (S.Y.A., S.P.E.).

3. Molecular Cardiology, Istituti Clinici Scientifici Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico and Department of Molecular Medicine, University of Pavia, Italy (A.M., D.K., S.G.P.).

4. European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (A.M., I.T., L.C., A.B., D.K., B.S., C.S., Y.D.W., S.D., A.A.M.W., E.R.B., J.T.-H., J.P.K., F.D., P.J.S., E.S.-B., S.G.P.).

5. Department of Cardiology I (I.T.), University Hospital Muenster, Germany.

6. Northern Ireland Inherited Cardiac Conditions Service, Belfast City Hospital, United Kingdom (A.R.M.).

7. Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy (L.C., C.S., P.J.S.).

8. Department of Medicine and Surgery, University of Milano-Bicocca, Italy (L.C.).

9. Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy (L.C.).

10. Heart Rhythm Services, Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada (A.D.K., T.M.R.).

11. Clinical Cardiovascular Research Center, University of Rochester Medical Center, NY (V.K., W.Z.).

12. Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Department of Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN (M.B., J.R.G., M.J.A.).

13. Departments of Medicine (M.B.S., N.C., D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

14. Division of Pediatric Cardiology, Department of Pediatrics, University of Louisville, KY (C.L.J.).

15. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan (T.A., K.S., W.S.).

16. Cardiac Inherited Disease Group New Zealand, Paediatric and Congenital Cardiac Services, Starship Children’s Hospital, Auckland (L.M., J.R.S.).

17. Pediatric Cardiology and Cardiac Arrhythmias Complex Unit, Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children’s Hospital and Research Institute, Rome, Italy (A.B., F.D.).

18. Children’s Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Canada (S.U., R.M.G.).

19. Division of Cardiology, Department of Pediatrics, University of Michigan Children’s Hospital, University of Michigan, Ann Arbor (B.D.).

20. Children’s Healthcare of Atlanta, Sibley Heart Center Cardiology, GA (P.F., L.M.K.).

21. Department of Epidemiology and Biostatistics (E.V.), University of California San Francisco.

22. Institute for Genetics of Heart Disease (B.S., S.D., E.S.-B.), University Hospital Muenster, Germany.

23. Cardiovascular Genetics Center, Montreal Heart Institute, Université de Montréal, Quebec, Canada (R.T., J., C.-T.).

24. Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Canada (H.J.D.).

25. Division of Cardiology, Queen’s University, Kingston, Ontario, Canada (C.S.S.).

26. Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George’s University of London, and St. George’s University Hospitals NHS Foundation Trust, United Kingdom (Y.D.W., E.R.B.).

27. Department of Pediatrics, Division of Pediatric Cardiology, and Department of Cell Biology, Duke University School of Medicine, Durham, NC (A.P.L.).

28. Amsterdam University Medical Centre, location AMC, Heart Center, Department of Clinical and Experimental Cardiology, The Netherlands (G.M.M., A.A.M.W.).

29. The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Denmark (J.T.-H.).

30. Department of Medicine, Division of Cardiology, Section of Cardiac Electrophysiology M.M.S.), University of California San Francisco.

31. Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (M.V.P.).

32. Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital and UCL Institute of Cardiovascular Science, London, United Kingdom (J.P.K.).

33. Department of Pediatric Cardiology, Cleveland Clinic, OH (P.F.A.).

34. Inherited Cardiac Arrhythmia Program, Boston Children’s Hospital, Harvard Medical School, MA (D.J.A.).

35. Department of Physiology and Department of Medicine, Toronto General Hospital, University of Toronto, Ontario, Canada (M.H.G.).

36. Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan (W.S.).

37. The Heart and Vascular Research Center, Metro-Health Campus, Case Western Reserve University, Cleveland, OH (E.S.K.).

38. Pharmacology (D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

39. Biomedical Informatics (D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

Abstract

Background: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration. Methods: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death. Results: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P <0.001). ECG penetrance for heterozygous genotype positive family members was 20.7% (29/140). A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR] 11.6 [95% CI, 2.6–52.2]; P =0.001). Event incidence did not differ significantly for Type 2 Jervell and Lange-Nielsen syndrome patients relative to the overall heterozygous cohort (10.5% [2/19]; HR 1.7 [95% CI, 0.3–10.8], P =0.590). The cumulative prevalence of the 32 KCNE1 variants in the Genome Aggregation Database, which is a human database of exome and genome sequencing data from now over 140 000 individuals, was 238-fold greater than the anticipated prevalence of all LQT5 combined (0.238% vs 0.001%). Conclusions: The present study suggests that putative/confirmed loss-of-function KCNE1 variants predispose to QT prolongation, however, the low ECG penetrance observed suggests they do not manifest clinically in the majority of individuals, aligning with the mild phenotype observed for Type 2 Jervell and Lange-Nielsen syndrome patients.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Long-QT Syndrome

2. Genetic causes of sudden cardiac death in the young

3. Channelopathies as Causes of Sudden Cardiac Death

4. Prevalence of the Congenital Long-QT Syndrome

5. Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of distant relatedness in biobanks to identify undiagnosed cases of Mendelian disease as applied to Long QT syndrome;Nature Communications;2024-08-29

2. High-throughput functional mapping of variants in an arrhythmia gene, KCNE1, reveals novel biology;Genome Medicine;2024-05-30

3. Stem cell models of inherited arrhythmias;Nature Cardiovascular Research;2024-03-21

4. Kardiogenetik in Deutschland – ein (Rück‑)Blick;Herzschrittmachertherapie + Elektrophysiologie;2024-02-28

5. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association;Circulation;2024-02-20